Aeterna Zentaris, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aeterna Zentaris, Inc. - overview
Established
1990
Location
Charleston, SC, US
Primary Industry
Biotechnology
About
Aeterna Zentaris, Inc. is a biopharmaceutical company based in the US, focusing on developing innovative therapies to address significant unmet medical needs in the healthcare sector. Founded in 1990 and headquartered in Charleston, US, Aeterna Zentaris, Inc. specializes in biopharmaceuticals.
The company has undergone strategic adjustments to enhance its focus on innovative therapies. Klaus Paulini serves as CEO, steering the company's vision since its inception, which was not a result of a merger or acquisition. Aeterna has been involved in 2 deals, with Roustan Capital notably investing in the company, although financial terms were not disclosed. Aeterna Zentaris, Inc.
offers a range of specialty biopharmaceutical products designed for healthcare providers and patients. Its key offerings include Macimorelin DX, a growth hormone secretagogue for diagnosing growth hormone deficiency, Avenanthramides, bioactive oat-derived compounds with anti-inflammatory benefits, and Oat Beta Glucan, known for managing cholesterol levels and supporting immune function. The company targets markets primarily in North America, Europe, and Asia and collaborates closely with hospitals, clinics, and pharmacies to ensure accessibility of its therapies. In the most recent fiscal year of 2023, Aeterna Zentaris reported a revenue of USD 4.
50 mn and an EBITDA of USD -16. 57 mn. The company's revenue is generated through strategic partnerships with healthcare providers and distributors, facilitating direct delivery of products to medical facilities and pharmacies, including sales of Macimorelin DX and Avenanthramides through negotiated contracts. Looking ahead, Aeterna Zentaris plans to introduce new products targeting the biopharmaceutical market and expand its operations into additional markets across Europe and Asia by 2025.
The recent investment from Roustan Capital will support these initiatives, providing resources necessary for product development and market entry, thereby enhancing the company's growth trajectory.
Current Investors
Roustan Capital
Primary Industry
Biotechnology
Sub Industries
Retail, Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.zentaris.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aeterna Zentaris, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Aeterna Zentaris, Inc. | - | ||||||||
| PIPE | Completed | Aeterna Zentaris, Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.